Paclitaxel nanoformulation - DFB Soria/Nanology

Drug Profile

Paclitaxel nanoformulation - DFB Soria/Nanology

Alternative Names: NanoPac; Nanotax; SOR007

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DFB Soria; Nanology
  • Developer bioskin; DFB Soria; Nanology; US Biotest Inc
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Actinic keratosis; Ovarian cancer; Pancreatic cancer; Pancreatic disorders; Prostate cancer; Skin cancer
  • Phase I Plaque psoriasis
  • Preclinical Cervical intraepithelial neoplasia; Non-small cell lung cancer

Most Recent Events

  • 16 Oct 2017 DFB Soria withdraws a phase II trial prior to enrolment for Cervical Intraepithelial Neoplasia in USA as the study never initiated (Topical, ointment) (NCT03143491)
  • 21 Sep 2017 Chemical structure information added
  • 15 Sep 2017 DFB Soria plans a phase II trial for Cervical Intraepithelial Neoplasia in USA (Topical, ointment) (NCT03143491)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top